Company News

2018
June 28

Gmax to Present at the PHA’s 2018 International PH Conference and Scie

June 28, 2018, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, announced today that it will present the preclinical and the phase 1 clinical trial results of its ETa antibody Getagozumab ...

2018
June 22

Gmax to Present at the 78th ADA Scientific Sessions

June 22, 2018, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, announced today that it will present the recent clinical progresses of its GLP-1R antibody Glutazumab ...

2018
May 03

Gmax Appoints Mr. Bing Zhu as CFO

Gmax, a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and Bibody development, today announced the appointment of Mr. Bing Zhu...

2018
January 26

Gmax R&D Team is Selected as “Leading Innovation Team”, Zhejiang P

The Gmax R&D Team on “Diabetes, obesity and pulmonary hypertension” is recently selected as the “Leading Innovation Team of the Zhejiang Province, 2017”.

2017
December 16

Gmax Initiates First-in-human Trial of Getagozumab (GMA301) in Austral

December 16, 2017, Gmax Biopharm LLC., a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, today ...


13 Records 123